A Post-market Registry of the MARIS-stent (Invatec) Implanted in the Superficial Femoral Artery

NCT ID: NCT01067885

Last Updated: 2012-04-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1051 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-04-30

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The MARIS Register is a prospective, multicenter registry of implantation in the superficial femoral artery (SFA) with a CE marked stent (Maris / Invatec) intended to capture initial angiographic success, complication rate and symptomatic related revascularization by following the clinical process and duplex examinations at 6 and 12 month.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recent data suggest that there is some evidence for a reduced restenosis rate for the implantation of a self expanding nitinol stent in the superficial femoral artery (SFA) compared to implantation of balloon expandable stents or single balloon inflation (ABSOLUTE study/FAST study).

The purpose of the Maris Register is to evaluate the primary nitinol stent implantation in an all comer population with diseased SFA.

The MARIS Register is a prospective, multicenter registry of the implantation of at least one at most five nitinol stents (Maris / Invatec) in the SFA without limitations for stenosis or occlusion length.

The registry includes 998 patients from 13 German investigational sites. Clinical data are captured on electronic case report forms

The primary endpoint is the target lesion revascularization after 12 month

Secondary endpoints are :

* Restenosis rate \> 50% according to ultrasound criteria
* Restenosis rate \> 70% according to ultrasound criteria
* Location of restenosis (proximal, middle, distal AFS)
* Number of stent fractures (grading according to FESTO criteria)
* Procedure related complication rate
* Vascular complication rate within 12 month
* Amputations within 12 month
* Deaths within 12 month

In order to measure the restenosis the peak systolic velocity (PSV) is to be measured in two sections during the duplex ultrasound examinations at 6 and 12 month. First measurement is performed 2cm proximal to the first stent, second measurement at the location where the maximum peak velocity over all lesions/all implanted stents is measured.

The clinical status includes the patient´s Fontaine classification.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MARIS-stent (Invatec)

stenting of SFA with Maris nitinol stent/s

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Maris nitinol stent (Invatec, Italy)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* stent implantation in SFA is possible
* existing SFA stenosis 70-100 % (visual estimation)
* absence of homodynamically relevant stenosis in A. poplitea
* at least one lower limb run off vessel

Exclusion Criteria

* pregnancy
* life expectancy less than 1 year
* coagulation disorder
* chronic anticoagulation therapy
* active gastrointestinal bleeding
* thrombolytic therapy within 72 hours before intervention
* hyperthyreosis
* severe contrast agent allergy
* allergy to concomittant medication
* severe liver disease
* thrombus in target lesion
* target lesion extend into A. poplitea
* severe calcification of target vessel, where no successful pre-dilatation is feasible
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic Vascular

INDUSTRY

Sponsor Role collaborator

Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hans Krankenbeg, MD

Role: PRINCIPAL_INVESTIGATOR

MCC Prof. Mathey, Prof. Schofer

References

Explore related publications, articles, or registry entries linked to this study.

Krankenberg H, Tubler T, Sixt S, Fischer M, Schmiedel R, Schulte KL, Balzer JO, Kieback A, Fiehn E, Wittenberg G, Ali T, Tiefenbacher C, Jahnke T, Steinkamp HJ, Wegscheider K, Treszl A, Ingwersen M, Zeller T. German multicenter real-world registry of stenting for superficial femoral artery disease: clinical results and predictive factors for revascularization. J Endovasc Ther. 2014 Aug;21(4):463-71. doi: 10.1583/13-4625R.1.

Reference Type DERIVED
PMID: 25101571 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MARIS-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

SuperNOVA Clinical Stenting Trial
NCT01292928 COMPLETED NA
EverFlex Post Approval Study
NCT01680835 COMPLETED NA